{"id":"NCT00622635","sponsor":"Novartis Pharmaceuticals","briefTitle":"A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)","officialTitle":"A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, 3-period, 14-day Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol (300 µg Once Daily [od]) in Patients With Moderate-to-severe COPD, Using Open-label Salmeterol (50 µg Twice Daily [Bis in Die, Bid]) as Active Control","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-01","primaryCompletion":"2008-07","completion":"2008-07","firstPosted":"2008-02-25","resultsPosted":"2011-08-18","lastUpdate":"2011-08-18"},"enrollment":68,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease"],"interventions":[{"type":"DRUG","name":"Indacaterol 300 μg","otherNames":[]},{"type":"DRUG","name":"Placebo to indacaterol","otherNames":[]},{"type":"DRUG","name":"Salmeterol 50 μg","otherNames":[]}],"arms":[{"label":"Indacaterol 300 μg - placebo to indacaterol - salmeterol 50 μg","type":"EXPERIMENTAL"},{"label":"Placebo to indacaterol - salmeterol 50 μg - indacaterol 300 μg","type":"EXPERIMENTAL"},{"label":"Salmeterol 50 μg - indacaterol 300 μg - placebo to indacaterol","type":"EXPERIMENTAL"},{"label":"Placebo to indacaterol - indacaterol 300 μg - salmeterol 50 μg","type":"EXPERIMENTAL"},{"label":"Indacaterol 300 μg - salmeterol 50 μg - placebo to indacaterol","type":"EXPERIMENTAL"},{"label":"Salmeterol 50 μg - placebo to indacaterol - indacaterol 300 μg","type":"EXPERIMENTAL"}],"summary":"This study was conducted to provide detailed information on the efficacy of indacaterol in terms of its effect on spirometry assessed forced expiratory volume in 1 second (FEV1) over a 24 hour time period.","primaryOutcome":{"measure":"Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose at the End of Each Treatment Period (Day 15)","timeFrame":"After 14 days","effectByArm":[{"arm":"Indacaterol 300 μg","deltaMin":1.46,"sd":0.027},{"arm":"Placebo to Indacaterol","deltaMin":1.26,"sd":0.027},{"arm":"Salmeterol 50 μg","deltaMin":1.37,"sd":0.027}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":11},"locations":{"siteCount":14,"countries":["United States","Belgium","Spain"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":66},"commonTop":["Back pain"]}}